Targeted Validation Samples
The dataset consists of targeted sequencing data obtained from an independent cohort of 11 patients to validate discriminative DMRs (differentially methylated regions) for Acute coronary syndrome (ACS) subtypes. The cohort includes 2 healthy subjects, 4 STEMI (ST-segment elevation myocardial infarction), 3 NSTEMI (non-ST-segment elevation myocardial infarction), and 2 UA (unstable angina) patients. The sequencing panel targeted 18,831 CpGs for analysis, reaching at least 5 reads coverage for 75% of the targeted CpGs in each sample. The sequencing was performed using the NEBNext Enzymatic Methyl-seq Module and the Nonacus Cell3TMTarget: Library Preparation kit, followed by probe hybridization, capture enrichment, and sequencing on the Novaseq 6000 platform, generating 400 million reads. The dataset is in raw fastq format.
- 2 samples
- DAC: EGAC00001003283
- Technology: Illumina NovaSeq 6000
- DS DUO:0000007 (version: 2021-02-23)disease specific researchThis data use permission indicates that use is allowed provided it is related to the specified disease.ModifiersMONDO:0005542
- NPUNCU DUO:0000018 (version: 2021-02-23)not for profit, non commercial use onlyThis data use modifier indicates that use of the data is limited to not-for-profit organizations and not-for-profit use, non-commercial use.
- PS DUO:0000027 (version: 2021-02-23)project specific restrictionThis data use modifier indicates that use is limited to use within an approved project.
- NCU DUO:0000046 (version: 2021-02-23)non-commercial use onlyThis data use modifier indicates that use of the data is limited to not-for-profit use.
Policy for Controlled-Access Data Access establishes a framework for responsible and ethical access to controlled-access data
The Policy for Controlled-Access Data Access establishes a framework for responsible and ethical access to controlled-access data. By implementing a Data Access Committee and rigorous application review processes, the policy ensures the protection of privacy, confidentiality, and compliance with legal and ethical requirements. It emphasizes data security, responsible data governance, and transparent communication with applicants and stakeholders. Regular policy reviews and updates guarantee alignment with advancements in technology, regulations, and ethical standards. By adhering to this policy, the DAC facilitates access to controlled-access data for research purposes while prioritizing privacy, confidentiality, and the responsible use of data.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |